Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Redhill Biopharma Ltd (NASDAQ:RDHL)

Delayed Data
As of Jul 22
 +0.39 / +3.32%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

RedHill Biopharma Ltd. is a biopharmaceutical company that engages in the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. Its current pipeline of proprietary products includes: RHB-105, RHB-104, BEKINDA (RHB-102), RHB-106, YELIVA (ABC294640), MESUPRON, RP101, RIZAPORT (RHB-103), and RHB-101. RHB-105 is an oral combination therapy for the treatment of Helicobacter pylori infection. RHB-104 is an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study. BEKINDA (RHB-102) is a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis. RHB-106 is an encapsulated bowel preparation. YELIVA (ABC294640) is an orally-administered SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications with a Phase I/II study initiated for refractory/relapsed diffuse large B-cell lymphoma (DLBCL). MESUPRON is a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumors. RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers. RIZAPORT™ (RHB-103) is an oral thin film formulation of rizatriptan for acute migraines. RHB-101 is a once-daily oral pill formulation of the cardio drug carvedilol. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Contact Information

RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv Tel Aviv 64739
P:(723) 541-3131
Investor Relations:



Other institutional19.30%
Mutual fund holders0.42%
Individual stakeholders--

Top Executives

Dror Ben-AsherChairman & Chief Executive Officer
Ori ShiloDeputy CEO- Finance & Operations
Micha Ben-ChorinChief Financial Officer
Reza FathiSenior Vice President-Research & Development
Clara FehrmannDirector-Clinical Operations